It's rare when the illness and cure are one in the same; but in AMAG Pharmaceuticals' case, iron is the problem and the solution. The biopharmaceutical company is focused on the development and commercialization of an iron compound to treat iron deficiency anemia (IDA). Its primary money maker is its Feraheme Injection to treat IDA in patients with chronic kidney disease (CKD). AMAG sells Feraheme in the US through its own sales force; in Europe, some Asian countries, Canada, India, and Turkey through an exclusive licensing agreement with Takeda. AMAG's other product, GastroMARK is marketed in the US, Europe, and other countries, and is used for delineating the bowel in abdominal imaging.